<p>波士頓，2026 年 2 月 10 日（全球新聞通訊社）——Galecto, Inc.（納斯達克：GLTO）是一家專注於開發新型治療藥物以重新定義血液癌症患者治療範式的生物製藥公司，今天宣佈其之前宣佈的承銷公開發行普通股的定價。Galecto 將以每股 19.00 美元的公開發行價格出售總計 14,473,685 股普通股。此外，Galecto 已授予承銷商一個為期 30 天的選擇權，以公開發行價格購買額外的 2,171,052 股普通股，扣除承銷折扣和佣金。預計 Galecto 從此次發行中獲得的總收益約為 2.75 億美元，未扣除承銷折扣和佣金及 Galecto 應支付的發行費用，並假設承銷商未行使購買額外股份的選擇權。</p>
<p>所有證券均由 Galecto 提供。此次發行預計將在 2026 年 2 月 12 日左右完成，具體以慣例的交割條件為準。</p>
<p>Jefferies、Leerink Partners、Evercore ISI 和 Guggenheim Securities 擔任此次發行的聯合賬簿管理人。</p>
<p>與這些證券相關的自動生效的貨架註冊聲明已於 2026 年 2 月 10 日提交給證券交易委員會（SEC）。此次發行僅通過書面招股説明書進行，包括構成有效註冊聲明一部分的招股説明書補充。與此次發行相關的初步招股説明書補充及隨附招股説明書已提交給 SEC，並可在 SEC 網站 www.sec.gov 上獲取。最終招股説明書補充及與此次發行相關的隨附招股説明書將提交給 SEC，並將在 SEC 網站 www.sec.gov 上提供，屆時可從以下機構獲取：Jefferies LLC（注意：股權承銷招股説明書部門，520 Madison Avenue, New York, New York 10022；電話：877-821-7388；或電子郵件：Prospectus_Department@Jefferies.com）；Leerink Partners LLC（注意：承銷部門，53 State Street, 40th Floor, Boston, Massachusetts 02109；電話：800-808-7425 ext. 6105；或電子郵件：syndicate@leerink.com）；Evercore Group L.L.C.（注意：股權資本市場，55 East 52nd Street, 35th Floor, New York, New York 10055；電話：888-474-0200；或電子郵件：ecm.prospectus@evercore.com）；或 Guggenheim Securities, LLC（注意：股權承銷部門，330 Madison Avenue, 8th Floor, New York, New York 10017；電話：212-518-9544；或電子郵件：GSEquityProspectusDelivery@guggenheimpartners.com）。</p>
<p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或其他司法管轄區進行這些證券的銷售，除非在任何此類州或其他司法管轄區的證券法下注冊或合格的情況下。</p>
<p><strong>關於 Galecto, Inc.</strong></p>
<p>Galecto, Inc.是一家臨牀階段的生物技術公司，正在推進一系列抗體治療藥物，以改變廣泛的血液癌症的治療。Galecto 的產品線包括一個高度差異化的突變鈣網蛋白（mut-CALR）驅動的骨髓增生性腫瘤組合，針對必需性血小板增多症和骨髓纖維化。Galecto 的產品線還包括 GB3226，這是一種首創的臨牀前雙重抑制劑，針對急性髓性白血病的多種遺傳亞型，抑制 ENL-YEATS 和 FLT3。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿中的某些聲明，除了純粹的歷史信息外，可能構成《聯邦證券法》意義上的 “前瞻性聲明”，包括根據 1995 年美國私人證券訴訟改革法的安全港條款的目的。這些前瞻性聲明包括但不限於關於 Galecto 對發行完成的預期；關於發行的慣常成交條件的滿足；以及與公司對其資產、產品線和業務未來的預期、希望、信念、意圖或戰略相關的明示或暗示聲明。此外，任何提及預測、預期或其他對未來事件或情況的描述，包括任何基本假設的聲明，都是前瞻性聲明。這些前瞻性聲明基於對未來發展及其潛在影響的當前預期和信念。無法保證影響公司的未來發展將是預期的那些。這些前瞻性聲明涉及多種風險、不確定性（其中一些超出公司的控制範圍）或其他假設，可能導致實際結果或表現與這些前瞻性聲明所表達或暗示的結果有實質性差異。這些風險和不確定性包括但不限於與承銷公開發行相關的慣常成交條件的滿足，以及在公司最近向 SEC 提交的文件中描述的 “風險因素”、“關於前瞻性聲明的警示信息” 或 “關於前瞻性聲明的警示説明” 標題下的那些不確定性和因素。如果這些風險或不確定性中的一個或多個實現，或者公司的任何假設被證明不正確，實際結果可能在實質上與這些前瞻性聲明中預測的結果有所不同。本新聞稿中的任何內容均不應被視為任何人對其中所列前瞻性聲明將會實現的陳述，或對這些前瞻性聲明所設想的任何結果將會實現的陳述。您不應對本新聞稿中的前瞻性聲明過度依賴，這些聲明僅在作出時有效，並且完全受此處警示聲明的限制。公司不承擔或接受對任何前瞻性聲明進行更新或修訂的任何義務。</p>
<p>媒體聯繫人：</p>
<p>Lia Dangelico</p>
<p>Deerfield Group</p>
<p>lia.dangelico@deerfieldgroup.com</p>
<p>投資者聯繫人：</p>
<p>Brian Ritchie</p>
<p>LifeSci Advisors</p>
<p>britchie@lifesciadvisors.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1qWTBNeU0zTkRJd016TXdJelV3TURBMk9UazVOdz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1qWTBNeU0zTkRJd016TXdJelV3TURBMk9UazVOdz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGU1YjE3OWEtYjE4My00MDNkLWEwMzMtZTE3NTIzM2NiMTU1LTUwMDA2OTk5Ny0yMDI2LTAyLTExLWVu/tiny/Galecto-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGU1YjE3OWEtYjE4My00MDNkLWEwMzMtZTE3NTIzM2NiMTU1LTUwMDA2OTk5Ny0yMDI2LTAyLTExLWVu/tiny/Galecto-Inc-.png"/></p>

醫藥突破 ETF - ALPS

基因改革 ETF - ARK

GLTO

<p>Galecto, Inc. 已將其承銷的公開發行定價為每股 19.00 美元，共計 14,473,685 股，旨在籌集約 2.75 億美元。此次發行包括承銷商在 30 天內購買額外 2,171,052 股的選擇權。該發行預計將在 2026 年 2 月 12 日左右完成，具體需遵循慣例條件。Jefferies、Leerink Partners、Evercore ISI 和 Guggenheim Securities 是聯合賬簿管理人。此公告是在向 SEC 提交有效的貨架註冊聲明後發佈的</p>

<p>BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expected to be approximately $275 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto and assuming no exercise of the underwriters’ option to purchase additional shares.</p>
<div class="lb-trans"><p>波士頓，2026 年 2 月 10 日（全球新聞通訊社）——Galecto, Inc.（納斯達克：GLTO）是一家專注於開發新型治療藥物以重新定義血液癌症患者治療範式的生物製藥公司，今天宣佈其之前宣佈的承銷公開發行普通股的定價。Galecto 將以每股 19.00 美元的公開發行價格出售總計 14,473,685 股普通股。此外，Galecto 已授予承銷商一個為期 30 天的選擇權，以公開發行價格購買額外的 2,171,052 股普通股，扣除承銷折扣和佣金。預計 Galecto 從此次發行中獲得的總收益約為 2.75 億美元，未扣除承銷折扣和佣金及 Galecto 應支付的發行費用，並假設承銷商未行使購買額外股份的選擇權。</p>
</div><p>All of the securities are being offered by Galecto. The offering is expected to close on or about February 12, 2026, subject to customary closing conditions.</p>
<div class="lb-trans"><p>所有證券均由 Galecto 提供。此次發行預計將在 2026 年 2 月 12 日左右完成，具體以慣例的交割條件為準。</p>
</div><p>Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.</p>
<div class="lb-trans"><p>Jefferies、Leerink Partners、Evercore ISI 和 Guggenheim Securities 擔任此次發行的聯合賬簿管理人。</p>
</div><p>An automatically effective shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on February 10, 2026. This offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov and, when available, may be obtained from: Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022; telephone: 877-821-7388; or email: Prospectus_Department@Jefferies.com); Leerink Partners LLC (Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109; telephone: 800-808-7425 ext. 6105; or email: syndicate@leerink.com); Evercore Group L.L.C. (Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055; telephone: 888-474-0200; or email: ecm.prospectus@evercore.com); or Guggenheim Securities, LLC (Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017; telephone: 212-518-9544; or email: GSEquityProspectusDelivery@guggenheimpartners.com).</p>
<div class="lb-trans"><p>與這些證券相關的自動生效的貨架註冊聲明已於 2026 年 2 月 10 日提交給證券交易委員會（SEC）。此次發行僅通過書面招股説明書進行，包括構成有效註冊聲明一部分的招股説明書補充。與此次發行相關的初步招股説明書補充及隨附招股説明書已提交給 SEC，並可在 SEC 網站 www.sec.gov 上獲取。最終招股説明書補充及與此次發行相關的隨附招股説明書將提交給 SEC，並將在 SEC 網站 www.sec.gov 上提供，屆時可從以下機構獲取：Jefferies LLC（注意：股權承銷招股説明書部門，520 Madison Avenue, New York, New York 10022；電話：877-821-7388；或電子郵件：Prospectus_Department@Jefferies.com）；Leerink Partners LLC（注意：承銷部門，53 State Street, 40th Floor, Boston, Massachusetts 02109；電話：800-808-7425 ext. 6105；或電子郵件：syndicate@leerink.com）；Evercore Group L.L.C.（注意：股權資本市場，55 East 52nd Street, 35th Floor, New York, New York 10055；電話：888-474-0200；或電子郵件：ecm.prospectus@evercore.com）；或 Guggenheim Securities, LLC（注意：股權承銷部門，330 Madison Avenue, 8th Floor, New York, New York 10017；電話：212-518-9544；或電子郵件：GSEquityProspectusDelivery@guggenheimpartners.com）。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或其他司法管轄區進行這些證券的銷售，除非在任何此類州或其他司法管轄區的證券法下注冊或合格的情況下。</p>
</div><p><strong>About Galecto, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Galecto, Inc.</strong></p>
</div><p>Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.</p>
<div class="lb-trans"><p>Galecto, Inc.是一家臨牀階段的生物技術公司，正在推進一系列抗體治療藥物，以改變廣泛的血液癌症的治療。Galecto 的產品線包括一個高度差異化的突變鈣網蛋白（mut-CALR）驅動的骨髓增生性腫瘤組合，針對必需性血小板增多症和骨髓纖維化。Galecto 的產品線還包括 GB3226，這是一種首創的臨牀前雙重抑制劑，針對急性髓性白血病的多種遺傳亞型，抑制 ENL-YEATS 和 FLT3。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding Galecto’s expectations regarding the consummation of the offering; the satisfaction of customary closing conditions with respect to the offering; and express or implied statements relating to the Company’s expectations, hopes, beliefs, intentions or strategies regarding the future of its assets, pipeline and business. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the satisfaction of customary closing conditions related to the underwritten public offering and those uncertainties and factors described under the headings “Risk Factors,” “Cautionary Information Regarding Forward-Looking Statements” or “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.</p>
<div class="lb-trans"><p>本新聞稿中的某些聲明，除了純粹的歷史信息外，可能構成《聯邦證券法》意義上的 “前瞻性聲明”，包括根據 1995 年美國私人證券訴訟改革法的安全港條款的目的。這些前瞻性聲明包括但不限於關於 Galecto 對發行完成的預期；關於發行的慣常成交條件的滿足；以及與公司對其資產、產品線和業務未來的預期、希望、信念、意圖或戰略相關的明示或暗示聲明。此外，任何提及預測、預期或其他對未來事件或情況的描述，包括任何基本假設的聲明，都是前瞻性聲明。這些前瞻性聲明基於對未來發展及其潛在影響的當前預期和信念。無法保證影響公司的未來發展將是預期的那些。這些前瞻性聲明涉及多種風險、不確定性（其中一些超出公司的控制範圍）或其他假設，可能導致實際結果或表現與這些前瞻性聲明所表達或暗示的結果有實質性差異。這些風險和不確定性包括但不限於與承銷公開發行相關的慣常成交條件的滿足，以及在公司最近向 SEC 提交的文件中描述的 “風險因素”、“關於前瞻性聲明的警示信息” 或 “關於前瞻性聲明的警示説明” 標題下的那些不確定性和因素。如果這些風險或不確定性中的一個或多個實現，或者公司的任何假設被證明不正確，實際結果可能在實質上與這些前瞻性聲明中預測的結果有所不同。本新聞稿中的任何內容均不應被視為任何人對其中所列前瞻性聲明將會實現的陳述，或對這些前瞻性聲明所設想的任何結果將會實現的陳述。您不應對本新聞稿中的前瞻性聲明過度依賴，這些聲明僅在作出時有效，並且完全受此處警示聲明的限制。公司不承擔或接受對任何前瞻性聲明進行更新或修訂的任何義務。</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒體聯繫人：</p>
</div><p>Lia Dangelico</p>
<div class="lb-trans"><p>Lia Dangelico</p>
</div><p>Deerfield Group</p>
<div class="lb-trans"><p>Deerfield Group</p>
</div><p>lia.dangelico@deerfieldgroup.com</p>
<div class="lb-trans"><p>lia.dangelico@deerfieldgroup.com</p>
</div><p>Investor Contact:</p>
<div class="lb-trans"><p>投資者聯繫人：</p>
</div><p>Brian Ritchie</p>
<div class="lb-trans"><p>Brian Ritchie</p>
</div><p>LifeSci Advisors</p>
<div class="lb-trans"><p>LifeSci Advisors</p>
</div><p>britchie@lifesciadvisors.com</p>
<div class="lb-trans"><p>britchie@lifesciadvisors.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1qWTBNeU0zTkRJd016TXdJelV3TURBMk9UazVOdz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1MjY0MyM3NDIwMzMwIzUwMDA2OTk5Nw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGU1YjE3OWEtYjE4My00MDNkLWEwMzMtZTE3NTIzM2NiMTU1LTUwMDA2OTk5Ny0yMDI2LTAyLTExLWVu/tiny/Galecto-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NGU1YjE3OWEtYjE4My00MDNkLWEwMzMtZTE3NTIzM2NiMTU1LTUwMDA2OTk5Ny0yMDI2LTAyLTExLWVu/tiny/Galecto-Inc-.png"/></p>

Galecto 宣佈 2.75 億美元的承銷公開發行定價 | GLTO 股票新聞